Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
about
Single dose oral ibuprofen for acute postoperative pain in adultsSingle dose oral rofecoxib for acute postoperative pain in adultsCOX-2 inhibitors: a CLASS act or Just VIGORously promotedSingle-dose rofecoxib for acute postoperative pain in adults: a quantitative systematic reviewIndividual patient meta-analysis of single-dose rofecoxib in postoperative painRelationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregationSafety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxibReview article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humansClassic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcersTargeting cyclooxygenase-2 with sodium butyrate and NSAIDs on colorectal adenoma/carcinoma cellsWhen to try COX-2-specific inhibitors. Safer than standard NSAIDs in some situations.Basic biology and clinical application of specific cyclooxygenase-2 inhibitors.A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirinAspirin and other anti-inflammatory drugs.Management of Inflammatory Pain with Selective COX-2 Inhibitors: Promises and Facts.Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia.COX-2 and Alzheimer's disease: potential roles in inflammation and neurodegeneration.Pain management in older adults: prevention and treatment.Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studiesA cohort study to evaluate cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients attending orthopedic department of a tertiary care hospitalNatural anti-inflammatory agents for pain reliefTherapeutic potential of COX-2 inhibitors in arthritis.COX-2 inhibitors compared and contrasted.Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors.Maximizing the safety of nonsteroidal anti-inflammatory drug use for postoperative dental pain: an evidence-based approach.Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin.Neuromodulatory role of endogenous interleukin-1β in acute seizures: possible contribution of cyclooxygenase-2Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind studyExpression of two WFDC1/ps20 isoforms in prostate stromal cells induces paracrine apoptosis through regulation of PTGS2/COX-2Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer.Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen.The efficacy of pre-operative oral medication of paracetamol, ibuprofen, and aceclofenac on the success of maxillary infiltration anesthesia in patients with irreversible pulpitis: A double-blind, randomized controlled clinical trialA comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin.Diesel exhaust particle extracts and associated polycyclic aromatic hydrocarbons inhibit Cox-2-dependent prostaglandin synthesis in murine macrophages and fibroblasts.Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.Experimental study of COX-2 selective and traditional non-steroidal anti-inflammatory drugs in total hip replacement.Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.Comparative study of anti-inflammatory and ulcerogenic activities of different cyclo-oxygenase inhibitors.Non-invasive different modalities of treatment for temporomandibular disorders: review of literature.
P2860
Q24239928-B037B494-08AF-4943-99C8-1E5A15E75096Q24240116-7B6B11A9-80E2-48AC-9727-75F3DAE7E53DQ24529085-14FB7375-C35F-4D0B-9330-21AC2BE2789CQ24796186-F4EC7BEF-DB83-4C13-AC87-14EC916D8FD9Q24799723-2C4E2640-A43D-41F6-89A9-437C88F83F42Q28165301-2A779042-B3C9-4FC6-919D-1BE63B0ADBB7Q28168018-458DC8B2-C8E5-4FE4-A988-7FA5CBFFFA3AQ28174827-5927E865-309F-4806-9ABA-314FEE41D128Q28184249-3D3F9920-E431-47C5-81C3-4CEB038FF571Q28213181-64F3D1CB-35C9-4F83-BC3C-0681C8E7CCF0Q33758859-DDE11F58-CC7A-479F-BAF0-7F8179E2A4CFQ33822140-D1E19493-FD67-4F4A-9309-E65290400AD9Q33952053-C1C5382B-C77F-4244-B0BB-1270545AEB2AQ34036177-A4C5665C-EE41-4792-8BDA-F39F0209F446Q34040447-D7A8801D-C310-4841-9997-21DFF207BF64Q34082384-388AD5EC-9820-4597-9852-DA94812720C7Q34119479-65F1DF9C-5282-4603-8F54-C7A1B61FE7DAQ34156390-9BF2E20F-3B7C-4196-BD56-C963992F891EQ34161193-E5124E73-3ED4-4D51-AA91-5FE9948975F8Q34259503-09821AF3-A44C-439B-9110-33783ED00FEDQ34444693-F8DEB976-38D1-4C79-B5B1-A2287FC87800Q34481579-90331E74-6820-4E95-BF94-4E63952B4C60Q34515513-F3A8E663-EBBD-434E-B8FF-344088C22067Q34982308-3998BF92-A4CA-4760-ADBC-C490B94D38A3Q35179307-BAA1F121-A70D-43C6-A0FA-278E5207D8D5Q35195182-E794E797-83BD-4B4E-9592-E34F38274CB7Q35361527-95D87976-286A-4A76-A596-699C56A8C261Q35574583-7C134DB1-50F8-4911-BEBC-BF6086E81769Q35595723-BA3D85DA-E3AA-4AE4-BA20-EEFCEECFAA13Q38775275-6BD9E9FB-A9E5-488B-86EF-7CE8FA351F2DQ39819644-B013F471-0CE2-4C4B-8730-3F531B13A966Q41020386-863C8A71-CBFE-480B-B0A3-D92F7C4961DFQ41675940-FD358D2F-A8BA-4D92-8575-64534F2171A6Q41947362-653EE230-06BD-4DB8-B476-9D0B2C46D2C9Q42811643-29CC29EC-DBFA-47F2-AD80-BD25609EBE72Q43742716-29820DF8-C1AE-4C5F-9516-1F5885007046Q46042261-31AA7C3E-E81E-4531-8C53-5529B8DD7C21Q46628463-EFAB67BD-48AE-4C5E-BB41-28BFE04505DDQ46798434-1AAA65F1-8E7E-469A-B1B6-B20D9CCAAC3FQ54939990-3A3FBE30-6D79-4666-A601-B655FC1616FF
P2860
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Characterization of rofecoxib ...... esia in the dental pain model.
@en
Characterization of rofecoxib ...... esia in the dental pain model.
@nl
type
label
Characterization of rofecoxib ...... esia in the dental pain model.
@en
Characterization of rofecoxib ...... esia in the dental pain model.
@nl
prefLabel
Characterization of rofecoxib ...... esia in the dental pain model.
@en
Characterization of rofecoxib ...... esia in the dental pain model.
@nl
P2093
P1476
Characterization of rofecoxib ...... esia in the dental pain model.
@en
P2093
De Lepeleire I
De Schepper P
Mehlisch DR
Riendeau D
Seibold JR
Van Hecken A
P304
P356
10.1016/S0009-9236(99)70113-X
P407
P577
1999-03-01T00:00:00Z